Disorders of Lipid Metabolism

[1]  P. Barter,et al.  Predictors of new-onset diabetes in patients treated with atorvastatin: results from 3 large randomized clinical trials. , 2011, Journal of the American College of Cardiology.

[2]  R. Collins,et al.  C-reactive protein concentration and the vascular benefits of statin therapy: an analysis of 20,536 patients in the Heart Protection Study. , 2011 .

[3]  L. Garrison,et al.  Patient characteristics and medical care costs associated with hypertriglyceridemia. , 2011, The American journal of cardiology.

[4]  Christopher P Cannon,et al.  Safety of anacetrapib in patients with or at high risk for coronary heart disease. , 2010, The New England journal of medicine.

[5]  R. Collins,et al.  Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170 000 participants in 26 randomised trials , 2010, The Lancet.

[6]  R. Collins,et al.  Intensive lowering of LDL cholesterol with 80 mg versus 20 mg simvastatin daily in 12 064 survivors of myocardial infarction: a double-blind randomised trial , 2010, The Lancet.

[7]  D. Grobbee,et al.  Effects of fibrates on cardiovascular outcomes: a systematic review and meta-analysis , 2010, The Lancet.

[8]  John B Buse,et al.  Effects of combination lipid therapy in type 2 diabetes mellitus. , 2010, The New England journal of medicine.

[9]  Michael Miller,et al.  Extended-release niacin or ezetimibe and carotid intima-media thickness. , 2009, The New England journal of medicine.

[10]  N. Keenan,et al.  Trends in high levels of low-density lipoprotein cholesterol in the United States, 1999-2006. , 2009, JAMA.

[11]  G. Franceschini,et al.  Functional Lecithin: Cholesterol Acyltransferase Is Not Required for Efficient Atheroprotection in Humans , 2009, Circulation.

[12]  John Turk,et al.  Identification of a Physiologically Relevant Endogenous Ligand for PPARα in Liver , 2009, Cell.

[13]  D. Holtzman,et al.  The Role of Apolipoprotein E in Alzheimer's Disease , 2009, Neuron.

[14]  S. Mudaliar,et al.  Effect of the dual peroxisome proliferator-activated receptor-α/γ agonist aleglitazar on risk of cardiovascular disease in patients with type 2 diabetes (SYNCHRONY): a phase II, randomised, dose-ranging study , 2009, The Lancet.

[15]  P. Tontonoz,et al.  LXR Regulates Cholesterol Uptake Through Idol-Dependent Ubiquitination of the LDL Receptor , 2009, Science.

[16]  Joseph L. Goldstein,et al.  Structure of N-Terminal Domain of NPC1 Reveals Distinct Subdomains for Binding and Transfer of Cholesterol , 2009, Cell.

[17]  R. Hegele,et al.  Narrative Review: Statin-Related Myopathy , 2009, Annals of Internal Medicine.

[18]  Børge G Nordestgaard,et al.  Genetically elevated lipoprotein(a) and increased risk of myocardial infarction. , 2009, JAMA.

[19]  S. Young,et al.  Chylomicronemia With a Mutant GPIHBP1 (Q115P) That Cannot Bind Lipoprotein Lipase , 2009, Arteriosclerosis, thrombosis, and vascular biology.

[20]  Joachim Herz,et al.  Apolipoprotein E receptors in the nervous system , 2009, Current opinion in lipidology.

[21]  K. Reue,et al.  Biochemistry, physiology, and genetics of GPAT, AGPAT, and lipin enzymes in triglyceride synthesis. , 2009, American journal of physiology. Endocrinology and metabolism.

[22]  Wei Zhang,et al.  Consuming fructose-sweetened, not glucose-sweetened, beverages increases visceral adiposity and lipids and decreases insulin sensitivity in overweight/obese humans. , 2009, The Journal of clinical investigation.

[23]  U. Navaneethan,et al.  Hypertriglyceridemic Pancreatitis: Presentation and Management , 2009, The American Journal of Gastroenterology.

[24]  J. Goldstein,et al.  The LDL receptor. , 2009, Arteriosclerosis, thrombosis, and vascular biology.

[25]  E. Rimm,et al.  Loss-of-function variants in endothelial lipase are a cause of elevated HDL cholesterol in humans. , 2009, The Journal of clinical investigation.

[26]  A. Goldberg,et al.  The use of niacin. , 2009, Journal of clinical lipidology.

[27]  D. Rader,et al.  The role of reverse cholesterol transport in animals and humans and relationship to atherosclerosis This work was supported by P01-HL22633 from the NHLBI. Published, JLR Papers in Press, December 8, 2008. , 2009, Journal of Lipid Research.

[28]  E. Stein,et al.  Other therapies for reducing low-density lipoprotein cholesterol: medications in development. , 2009, Endocrinology and metabolism clinics of North America.

[29]  P. Toth.  Novel therapies for increasing serum levels of HDL. , 2009, Endocrinology and metabolism clinics of North America.

[30]  I. Goldberg.  Hypertriglyceridemia: impact and treatment. , 2009, Endocrinology and metabolism clinics of North America.

[31]  P. Kris-Etherton,et al.  Lifestyle approaches and dietary strategies to lower LDL-cholesterol and triglycerides and raise HDL-cholesterol. , 2009, Endocrinology and metabolism clinics of North America.

[32]  P. Thompson,et al.  Managing statin myopathy. , 2009, Endocrinology and metabolism clinics of North America.

[33]  D. Mozaffarian,et al.  Omega-6 Fatty Acids and Risk for Cardiovascular Disease: A Science Advisory From the American Heart Association Nutrition Subcommittee of the Council on Nutrition, Physical Activity, and Metabolism; Council on Cardiovascular Nursing; and Council on Epidemiology and Prevention , 2009, Circulation.

[34]  Gordon H Guyatt,et al.  Association between change in high density lipoprotein cholesterol and cardiovascular disease morbidity and mortality: systematic review and meta-regression analysis , 2009, BMJ : British Medical Journal.

[35]  S. O’Rahilly,et al.  Postreceptor insulin resistance contributes to human dyslipidemia and hepatic steatosis. , 2009, The Journal of clinical investigation.

[36]  D. Mozaffarian,et al.  Heart disease and stroke statistics--2009 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. , 2009, Circulation.

[37]  D. Mozaffarian,et al.  Heart disease and stroke statistics--2009 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. , 2009, Circulation.

[38]  K. Moore,et al.  Loss of SR-A and CD36 Activity Reduces Atherosclerotic Lesion Complexity Without Abrogating Foam Cell Formation in Hyperlipidemic Mice , 2009, Arteriosclerosis, thrombosis, and vascular biology.

[39]  J. O’Connell,et al.  A Null Mutation in Human APOC3 Confers a Favorable Plasma Lipid Profile and Apparent Cardioprotection , 2008, Science.

[40]  P. Libby,et al.  Toll-Like Receptor 2 Mediates Apolipoprotein CIII–Induced Monocyte Activation: Retracted , 2008, Circulation research.

[41]  P. Libby,et al.  Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. , 2008, The New England journal of medicine.

[42]  K. Williams.  Molecular processes that handle -- and mishandle -- dietary lipids. , 2008, The Journal of clinical investigation.

[43]  N. Delsaux,et al.  Effects of Six APOA5 Variants, Identified in Patients With Severe Hypertriglyceridemia, on In Vitro Lipoprotein Lipase Activity and Receptor Binding , 2008, Arteriosclerosis, thrombosis, and vascular biology.

[44]  Frits Mastik,et al.  Effects of the Direct Lipoprotein-Associated Phospholipase A2 Inhibitor Darapladib on Human Coronary Atherosclerotic Plaque , 2008, Circulation.

[45]  Maria M. Mihaylova,et al.  AMPK and PPARδ Agonists Are Exercise Mimetics , 2008, Cell.

[46]  V. Kamanna,et al.  Nicotinic acid: recent developments , 2008, Current opinion in cardiology.

[47]  L. Glimcher,et al.  Regulation of Hepatic Lipogenesis by the Transcription Factor XBP1 , 2008, Science.

[48]  S. Kathiresan.  A PCSK9 missense variant associated with a reduced risk of early-onset myocardial infarction. , 2008, The New England journal of medicine.

[49]  Yukio Horikawa,et al.  ChREBP: a glucose-activated transcription factor involved in the development of metabolic syndrome. , 2008, Endocrine journal.

[50]  G. Watts,et al.  Apolipoprotein C-III: understanding an emerging cardiovascular risk factor. , 2008, Clinical science.

[51]  M. Nieminen,et al.  Apolipoprotein E polymorphism is associated with both carotid and coronary atherosclerosis in patients with coronary artery disease. , 2008, Nutrition, metabolism, and cardiovascular diseases : NMCD.

[52]  J. Tomassini,et al.  Lipid-altering efficacy and safety of ezetimibe/simvastatin coadministered with extended-release niacin in patients with type IIa or type IIb hyperlipidemia. , 2008, Journal of the American College of Cardiology.

[53]  J. Baillargeon,et al.  Impaired plasma nonesterified fatty acid tolerance is an early defect in the natural history of type 2 diabetes. , 2008, The Journal of clinical endocrinology and metabolism.

[54]  Catherine M Champagne,et al.  The evidence for dietary prevention and treatment of cardiovascular disease. , 2008, Journal of the American Dietetic Association.

[55]  T. Willson,et al.  Activation of Peroxisome Proliferator–Activated Receptor (PPAR)δ Promotes Reversal of Multiple Metabolic Abnormalities, Reduces Oxidative Stress, and Increases Fatty Acid Oxidation in Moderately Obese Men , 2008, Diabetes.

[56]  R Peto,et al.  Efficacy of cholesterol-lowering therapy in 18,686 people with diabetes in 14 randomised trials of statins: a meta-analysis. , 2008, Lancet.

[57]  P. Pajukanta,et al.  Mutations in LMF1 cause combined lipase deficiency and severe hypertriglyceridemia , 2007, Nature Genetics.

[58]  J. Armitage,et al.  The safety of statins in clinical practice , 2007, The Lancet.

[59]  M. Caulfield,et al.  Effects of torcetrapib in patients at high risk for coronary events. , 2007, The New England journal of medicine.

[60]  D. Rader.  Illuminating HDL--is it still a viable therapeutic target? , 2007, The New England journal of medicine.

[61]  S. Gordon,et al.  Macrophage scavenger receptors and host-derived ligands. , 2007, Methods.

[62]  Hitoshi Shimano,et al.  Crucial role of a long-chain fatty acid elongase, Elovl6, in obesity-induced insulin resistance , 2007, Nature Medicine.

[63]  K. Korach,et al.  27-Hydroxycholesterol is an endogenous SERM that inhibits the cardiovascular effects of estrogen , 2007, Nature Medicine.

[64]  P. Thompson,et al.  Primary biliary cirrhosis, hyperlipidemia, and atherosclerotic risk: a systematic review. , 2007, Atherosclerosis.

[65]  J. Danesh,et al.  Association of apolipoprotein E genotypes with lipid levels and coronary risk. , 2007, JAMA.

[66]  M. Lane,et al.  Brain fatty acid synthase activates PPARα to maintain energy homeostasis , 2007 .

[67]  B. Nordestgaard,et al.  Nonfasting triglycerides and risk of myocardial infarction, ischemic heart disease, and death in men and women. , 2007, JAMA.

[68]  P. Ridker,et al.  Fasting compared with nonfasting triglycerides and risk of cardiovascular events in women. , 2007, JAMA.

[69]  G. Watts,et al.  Dose-dependent effect of rosuvastatin on apolipoprotein B-100 kinetics in the metabolic syndrome. , 2007, Atherosclerosis.

[70]  H. Davis,et al.  Zetia: inhibition of Niemann-Pick C1 Like 1 (NPC1L1) to reduce intestinal cholesterol absorption and treat hyperlipidemia. , 2007, Journal of atherosclerosis and thrombosis.

[71]  J. Mckenney,et al.  Comparative effects on lipid levels of combination therapy with a statin and extended-release niacin or ezetimibe versus a statin alone (the COMPELL study). , 2007, Atherosclerosis.

[72]  S. Young,et al.  Glycosylphosphatidylinositol-anchored high-density lipoprotein-binding protein 1 plays a critical role in the lipolytic processing of chylomicrons. , 2007, Cell metabolism.

[73]  M. Gale,et al.  Hepatitis C virus production by human hepatocytes dependent on assembly and secretion of very low-density lipoproteins , 2007, Proceedings of the National Academy of Sciences.

[74]  A. Soutar,et al.  Mechanisms of Disease: genetic causes of familial hypercholesterolemia , 2007, Nature Clinical Practice Cardiovascular Medicine.

[75]  Y. Matsuzawa,et al.  Effects of eicosapentaenoic acid on major coronary events in hypercholesterolaemic patients (JELIS): a randomised open-label, blinded endpoint analysis , 2007, The Lancet.

[76]  Jean-Claude Tardif,et al.  Effect of torcetrapib on the progression of coronary atherosclerosis. , 2007, The New England journal of medicine.

[77]  J. Mckenney,et al.  Safety considerations with gastrointestinally active lipid-lowering drugs. , 2007, The American journal of cardiology.

[78]  H. Bays,et al.  Safety considerations with niacin therapy. , 2007, The American journal of cardiology.

[79]  H. Bays.  Safety considerations with omega-3 fatty acid therapy. , 2007, The American journal of cardiology.

[80]  Jayaram Radhakrishnan,et al.  LRP6 Mutation in a Family with Early Coronary Disease and Metabolic Risk Factors , 2007, Science.

[81]  E. Duffield,et al.  Efficacy and safety of rosuvastatin 40 mg alone or in combination with ezetimibe in patients at high risk of cardiovascular disease (results from the EXPLORER study). , 2007, The American journal of cardiology.

[82]  Paul Schoenhagen,et al.  Statins, high-density lipoprotein cholesterol, and regression of coronary atherosclerosis. , 2007, JAMA.

[83]  Richard E Gregg,et al.  Inhibition of microsomal triglyceride transfer protein in familial hypercholesterolemia. , 2007, The New England journal of medicine.

[84]  P. Neuvonen,et al.  Drug interactions with lipid‐lowering drugs: Mechanisms and clinical relevance , 2006, Clinical pharmacology and therapeutics.

[85]  J. Flier,et al.  TLR4 links innate immunity and fatty acid-induced insulin resistance. , 2006, The Journal of clinical investigation.

[86]  J. Kastelein,et al.  Potent Reduction of Apolipoprotein B and Low-Density Lipoprotein Cholesterol by Short-Term Administration of an Antisense Inhibitor of Apolipoprotein B , 2006, Circulation.

[87]  H. Bays,et al.  Lipid-lowering effects of colesevelam HCl in combination with ezetimibe* , 2006, Current medical research and opinion.

[88]  K. Reue,et al.  Lipin Expression Is Attenuated in Adipose Tissue of Insulin-Resistant Human Subjects and Increases With Peroxisome Proliferator–Activated Receptor γ Activation , 2006, Diabetes.

[89]  S. Grundy,et al.  Reduction of low-density lipoprotein cholesterol in patients with coronary heart disease and metabolic syndrome: analysis of the Treating to New Targets study , 2006, The Lancet.

[90]  S. Reddy,et al.  Mechanisms of Disease: proatherogenic HDL—an evolving field , 2006, Nature Clinical Practice Endocrinology &Metabolism.

[91]  K. Kalunian,et al.  Proinflammatory high-density lipoprotein as a biomarker for atherosclerosis in patients with systemic lupus erythematosus and rheumatoid arthritis. , 2006, Arthritis and rheumatism.

[92]  W. Harris,et al.  Why do omega-3 fatty acids lower serum triglycerides? , 2006, Current opinion in lipidology.

[93]  J. Wylie-Rosett,et al.  Diet and Lifestyle Recommendations Revision 2006: A Scientific Statement From the American Heart Association Nutrition Committee , 2006, Circulation.

[94]  S. Offermanns.  The nicotinic acid receptor GPR109A (HM74A or PUMA-G) as a new therapeutic target. , 2006, Trends in pharmacological sciences.

[95]  Harlan M Krumholz,et al.  Withdrawn: P68 , 2006 .

[96]  Hui Shen,et al.  Rapid Responses , 2022 .

[97]  K. Nakajima,et al.  The oxidative modification hypothesis of atherosclerosis: the comparison of atherogenic effects on oxidized LDL and remnant lipoproteins in plasma. , 2006, Clinica chimica acta; international journal of clinical chemistry.

[98]  N. Chalasani,et al.  An assessment of statin safety by hepatologists. , 2006, The American journal of cardiology.

[99]  M. Bottorff,et al.  Statin safety and drug interactions: clinical implications. , 2006, The American journal of cardiology.

[100]  B. Kasiske,et al.  An assessment of statin safety by nephrologists. , 2006, The American journal of cardiology.

[101]  H. Bays.  Statin safety: an overview and assessment of the data--2005. , 2006, The American journal of cardiology.

[102]  T. A. Jacobson,et al.  Statin safety: lessons from new drug applications for marketed statins. , 2006, The American journal of cardiology.

[103]  D. Mozaffarian,et al.  Trans fatty acids and cardiovascular disease. , 2006, The New England journal of medicine.

[104]  Raimund Erbel,et al.  Effect of very high-intensity statin therapy on regression of coronary atherosclerosis: the ASTEROID trial. , 2006, JAMA.

[105]  Jonathan C. Cohen,et al.  Sequence variations in PCSK9, low LDL, and protection against coronary heart disease. , 2006, The New England journal of medicine.

[106]  Carl J Pepine,et al.  Effect of ACAT inhibition on the progression of coronary atherosclerosis. , 2006, The New England journal of medicine.

[107]  G. Shulman,et al.  Reversal of diet-induced hepatic steatosis and hepatic insulin resistance by antisense oligonucleotide inhibitors of acetyl-CoA carboxylases 1 and 2. , 2006, The Journal of clinical investigation.

[108]  W. Insull.  Clinical Utility of Bile Acid Sequestrants in the Treatment of Dyslipidemia: A Scientific Review , 2006, Southern medical journal.

[109]  P Glasziou,et al.  Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial , 2005, The Lancet.

[110]  O. Faergeman,et al.  High-dose atorvastatin vs usual-dose simvastatin for secondary prevention after myocardial infarction: the IDEAL study: a randomized controlled trial. , 2005, JAMA.

[111]  B. Patris,et al.  CD36 involvement in orosensory detection of dietary lipids, spontaneous fat preference, and digestive secretions. , 2005, The Journal of clinical investigation.

[112]  Fernando Costa,et al.  Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement. , 2005, Circulation.

[113]  P. Sorlie,et al.  Trends in serum lipids and lipoproteins of adults, 1960-2002. , 2005, JAMA.

[114]  R. Collins,et al.  Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90 056 participants in 14 randomised trials of statins , 2005, The Lancet.

[115]  D. Mangelsdorf,et al.  Retinoid x receptor heterodimers in the metabolic syndrome. , 2005, The New England journal of medicine.

[116]  W. März,et al.  Atorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysis. , 2005, The New England journal of medicine.

[117]  M. Hussain,et al.  Intestinal lipoprotein assembly , 2005, Current opinion in lipidology.

[118]  G. S. Shelness,et al.  Evolution and mechanism of apolipoprotein B-containing lipoprotein assembly , 2005, Current opinion in lipidology.

[119]  D. Matern,et al.  Fetal Fatty Acid Oxidation Disorders, Their Effect on Maternal Health and Neonatal Outcome: Impact of Expanded Newborn Screening on Their Diagnosis and Management , 2005, Pediatric Research.

[120]  Philip J. Barter,et al.  Intensive lipid lowering with atorvastatin in patients with stable coronary disease. , 2005, The New England journal of medicine.

[121]  C. Kent.  Regulatory enzymes of phosphatidylcholine biosynthesis: a personal perspective. , 2005, Biochimica et biophysica acta.

[122]  Robert V Farese,et al.  Atvb in Focus Novel Approaches to the Treatment of Dyslipidemia Inhibition of Triglyceride Synthesis as a Treatment Strategy for Obesity Lessons from Dgat1-deficient Mice Dgat Enzymes and Triglyceride Synthesis , 2022 .

[123]  P. Tso,et al.  The role of apolipoprotein AIV on the control of food intake. , 2005, Current drug targets.

[124]  E. Fisher,et al.  Overexpression of PCSK9 accelerates the degradation of the LDLR in a post-endoplasmic reticulum compartment. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[125]  D. Steinberg.  Thematic review series: the pathogenesis of atherosclerosis. An interpretive history of the cholesterol controversy: part II: the early evidence linking hypercholesterolemia to coronary disease in humans. , 2005, Journal of lipid research.

[126]  A. Gotto,et al.  A Randomized Trial of a Strategy for Increasing High-Density Lipoprotein Cholesterol Levels: Effects on Progression of Coronary Heart Disease and Clinical Events , 2005, Annals of Internal Medicine.

[127]  S. Grinspoon,et al.  Cardiovascular risk and body-fat abnormalities in HIV-infected adults. , 2005, The New England journal of medicine.

[128]  Jeannie K. Lee,et al.  Arterial Biology for the Investigation of the Treatment Effects of Reducing Cholesterol (ARBITER) 2: A Double-Blind, Placebo-Controlled Study of Extended-Release Niacin on Atherosclerosis Progression in Secondary Prevention Patients Treated With Statins , 2004, Circulation.

[129]  K. Adeli,et al.  Hepatic Regulation of Apolipoprotein B , 2004, Reviews in Endocrine & Metabolic Disorders.

[130]  S. Yusuf,et al.  Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study , 2004, The Lancet.

[131]  John H Fuller,et al.  Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial , 2004, The Lancet.

[132]  M. Davidson,et al.  Combination therapy in the management of complex dyslipidemias , 2004, Current opinion in lipidology.

[133]  R. Blumenthal,et al.  Treatment of hyperlipidemia in cardiac transplant recipients. , 2004, American heart journal.

[134]  A. Soutar,et al.  Current management of severe homozygous hypercholesterolaemias , 2004, Current opinion in lipidology.

[135]  Sander M Houten,et al.  Bile acids lower triglyceride levels via a pathway involving FXR, SHP, and SREBP-1c. , 2004, The Journal of clinical investigation.

[136]  M. Tsuda,et al.  Substitution of transdermal estradiol during oral estrogen-progestin therapy in postmenopausal women: effects on hypertriglyceridemia , 2004, Menopause.

[137]  A. Goldberg,et al.  Efficacy and safety of ezetimibe coadministered with simvastatin in patients with primary hypercholesterolemia: a randomized, double-blind, placebo-controlled trial. , 2004, Mayo Clinic proceedings.

[138]  D. Rader,et al.  Effects of an inhibitor of cholesteryl ester transfer protein on HDL cholesterol. , 2004, The New England journal of medicine.

[139]  S. Paranjothy,et al.  National cross sectional survey to determine whether the decision to delivery interval is critical in emergency caesarean section , 2004, BMJ : British Medical Journal.

[140]  Paul Schoenhagen,et al.  Effect of intensive compared with moderate lipid-lowering therapy on progression of coronary atherosclerosis: a randomized controlled trial. , 2004, JAMA.

[141]  J. Kane,et al.  Ezetimibe Effectively Reduces Plasma Plant Sterols in Patients With Sitosterolemia , 2004, Circulation.

[142]  M. Moghadasian.  Cerebrotendinous xanthomatosis: clinical course, genotypes and metabolic backgrounds. , 2004, Clinical and investigative medicine. Medecine clinique et experimentale.

[143]  B. G. Brown,et al.  Safety and tolerability of simvastatin plus niacin in patients with coronary artery disease and low high-density lipoprotein cholesterol (The HDL Atherosclerosis Treatment Study). , 2004, The American journal of cardiology.

[144]  B. Hahn.  Systemic lupus erythematosus and accelerated atherosclerosis. , 2003, The New England journal of medicine.

[145]  Paul Schoenhagen,et al.  Effect of recombinant ApoA-I Milano on coronary atherosclerosis in patients with acute coronary syndromes: a randomized controlled trial. , 2003, JAMA.

[146]  A. Soutar,et al.  Genetics, Clinical Phenotype, and Molecular Cell Biology of Autosomal Recessive Hypercholesterolemia , 2003, Arteriosclerosis, thrombosis, and vascular biology.

[147]  R. Lipton,et al.  Unique lipoprotein phenotype and genotype associated with exceptional longevity. , 2003, JAMA.

[148]  G. Cheng,et al.  Crosstalk between LXR and toll-like receptor signaling mediates bacterial and viral antagonism of cholesterol metabolism. , 2003, Molecular cell.

[149]  T. Osborne,et al.  Thyroid Hormone Regulation and Cholesterol Metabolism Are Connected through Sterol Regulatory Element-binding Protein-2 (SREBP-2)* , 2003, Journal of Biological Chemistry.

[150]  A. Dyer,et al.  Major Risk Factors as Antecedents of Fatal and Nonfatal Coronary Heart Disease Events , 2003 .

[151]  Eric J Topol,et al.  Prevalence of conventional risk factors in patients with coronary heart disease. , 2003, JAMA.

[152]  Lawrence A Leiter,et al.  Effects of a dietary portfolio of cholesterol-lowering foods vs lovastatin on serum lipids and C-reactive protein. , 2003, JAMA.

[153]  J. Weissenbach,et al.  Mutations in PCSK9 cause autosomal dominant hypercholesterolemia , 2003, Nature Genetics.

[154]  J. Schaffer,et al.  Lipotoxicity: when tissues overeat , 2003, Current opinion in lipidology.

[155]  P. Sager,et al.  Effect of Ezetimibe Coadministered With Atorvastatin in 628 Patients With Primary Hypercholesterolemia: A Prospective, Randomized, Double-Blind Trial , 2003, Circulation.

[156]  T. Rabelink,et al.  Hypertriglyceridemia in patients with chronic renal failure: possible mechanisms. , 2003, Kidney international. Supplement.

[157]  J. Taipale,et al.  A defective response to Hedgehog signaling in disorders of cholesterol biosynthesis , 2003, Nature Genetics.

[158]  R. Collins,et al.  Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial—Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial , 2003, The Lancet.

[159]  P. Thompson,et al.  Statin-associated myopathy. , 2003, JAMA.

[160]  R. Suresh,et al.  Effects of ezetimibe, a new cholesterol absorption inhibitor, on plasma lipids in patients with primary hypercholesterolemia. , 2003, European heart journal.

[161]  D. Atkins,et al.  American Heart Association guidelines for primary prevention of atherosclerotic cardiovascular disease beginning in childhood. , 2003, The Journal of pediatrics.

[162]  A. von Eckardstein,et al.  Androgens and coronary artery disease. , 2003, Endocrine reviews.

[163]  F. Pfrieger.  Role of cholesterol in synapse formation and function. , 2003, Biochimica et biophysica acta.

[164]  A. Jenkins,et al.  Effects of insulin resistance and type 2 diabetes on lipoprotein subclass particle size and concentration determined by nuclear magnetic resonance. , 2003, Diabetes.

[165]  K. Berge.  Sitosterolemia: a gateway to new knowledge about cholesterol metabolism , 2003, Annals of medicine.

[166]  R. Eckel,et al.  Lipoprotein lipase : genetics , lipid uptake , and regulation , 2002 .

[167]  Lawrence J Appel,et al.  Fish consumption, fish oil, omega-3 fatty acids, and cardiovascular disease. , 2002, Arteriosclerosis, thrombosis, and vascular biology.

[168]  R. Suresh,et al.  Efficacy and safety of a potent new selective cholesterol absorption inhibitor, ezetimibe, in patients with primary hypercholesterolemia. , 2002, The American journal of cardiology.

[169]  R. Subramanian,et al.  Effects of fibrates on metabolism of statins in human hepatocytes. , 2002, Drug metabolism and disposition: the biological fate of chemicals.

[170]  S. Anant,et al.  Identification and regulation of protein components of the apolipoprotein B mRNA editing enzyme. A complex event. , 2002, Trends in cardiovascular medicine.

[171]  Joseph L. Goldstein,et al.  Structure of the LDL Receptor Extracellular Domain at Endosomal pH , 2002, Science.

[172]  H. Gylling,et al.  Inheritance of cholesterol metabolism of probands with high or low cholesterol absorption DOI 10.1194/jlr.M200155-JLR200 , 2002, Journal of Lipid Research.

[173]  Dorothy Bedford,et al.  Influence of atorvastatin and simvastatin on apolipoprotein B metabolism in moderate combined hyperlipidemic subjects with low VLDL and LDL fractional clearance rates. , 2002, Atherosclerosis.

[174]  Claude Lenfant,et al.  ACC/AHA/NHLBI clinical advisory on the use and safety of statins. , 2002, Journal of the American College of Cardiology.

[175]  B. Yandell,et al.  Loss of stearoyl–CoA desaturase-1 function protects mice against adiposity , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[176]  AndrewJ. S. Coats.  MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20 536 high-risk individuals: a randomised placebocontrolled trial , 2002, The Lancet.

[177]  Celeste Eng,et al.  Human cholesterol 7alpha-hydroxylase (CYP7A1) deficiency has a hypercholesterolemic phenotype. , 2002, The Journal of clinical investigation.

[178]  A. Zwinderman,et al.  Efficacy and Safety of a Novel Cholesteryl Ester Transfer Protein Inhibitor, JTT-705, in Humans: A Randomized Phase II Dose-Response Study , 2002, Circulation.

[179]  Jonathan C. Cohen,et al.  Autosomal recessive hypercholesterolaemia in Sardinia, Italy, and mutations in ARH: a clinical and molecular genetic analysis , 2002, The Lancet.

[180]  M. McGovern,et al.  Long-term safety and efficacy of a once-daily niacin/lovastatin formulation for patients with dyslipidemia. , 2002, The American journal of cardiology.

[181]  N. Abumrad,et al.  Role of CD36 in membrane transport of long-chain fatty acids , 2002, Current opinion in clinical nutrition and metabolic care.

[182]  E. Bolson,et al.  Simvastatin and niacin, antioxidant vitamins, or the combination for the prevention of coronary disease. , 2001, The New England journal of medicine.

[183]  Jonathan C. Cohen,et al.  An Apolipoprotein Influencing Triglycerides in Humans and Mice Revealed by Comparative Sequencing , 2001, Science.

[184]  D. Hunninghake,et al.  Effectiveness of colesevelam hydrochloride in decreasing LDL cholesterol in patients with primary hypercholesterolemia: a 24-week randomized controlled trial. , 2001, Mayo Clinic proceedings.

[185]  D. Hunninghake,et al.  Coadministration of colesevelam hydrochloride with atorvastatin lowers LDL cholesterol additively. , 2001, Atherosclerosis.

[186]  D. Strickland,et al.  LRP: a multifunctional scavenger and signaling receptor. , 2001, The Journal of clinical investigation.

[187]  E. Barrett-Connor,et al.  Effect of raloxifene on serum triglycerides in postmenopausal women: influence of predisposing factors for hypertriglyceridemia. , 2001, Clinical therapeutics.

[188]  M. Ito,et al.  Colesevelam Hydrochloride: A Novel Bile Acid-Binding Resin , 2001, The Annals of pharmacotherapy.

[189]  R. Cantor,et al.  The apoAI-CIII-AIV gene cluster. , 2001, Atherosclerosis.

[190]  J. Mckenney,et al.  Low‐dose combination therapy with colesevelam hydrochloride and lovastatin effectively decreases low‐density lipoprotein cholesterol in patients with primary hypercholesterolemia , 2001, Clinical cardiology.

[191]  R. Lawn,et al.  ABCA1. The gatekeeper for eliminating excess tissue cholesterol. , 2001, Journal of lipid research.

[192]  J. Gaziano,et al.  Efficacy and safety of combination simvastatin and colesevelam in patients with primary hypercholesterolemia. , 2001, The American journal of medicine.

[193]  I. Goldberg,et al.  Caloric and vitamin distribution by LpL 4. Synthesis and processing of lipases 5. Lipoproteins and regulation of the lipolysis reaction 6. Apolipoproteins 7. Non-enzymatic actions of lipoprotein lipase 8. Structure-function analysis of lipoprotein lipase 9.Genetic variation in lipoprotein lipase 10. , 2002 .

[194]  M. Stiles,et al.  Drug Interactions with Colesevelam Hydrochloride, a Novel, Potent Lipid-Lowering Agent , 2000, Cardiovascular Drugs and Therapy.

[195]  N. Grishin,et al.  Accumulation of dietary cholesterol in sitosterolemia caused by mutations in adjacent ABC transporters. , 2000, Science.

[196]  R. Kleinpell,et al.  Colesevelam hydrochloride: a non-absorbed, polymeric cholesterol-lowering agent , 2000, Expert opinion on investigational drugs.

[197]  G. Lowe,et al.  Lipoprotein-associated phospholipase A2 as an independent predictor of coronary heart disease. West of Scotland Coronary Prevention Study Group. , 2000, The New England journal of medicine.

[198]  M. Elisaf,et al.  Tamoxifen-induced severe hypertriglyceridemia and pancreatitis. , 2000, Annals of oncology : official journal of the European Society for Medical Oncology.

[199]  B. Psaty,et al.  Cardiovascular disease mortality in familial forms of hypertriglyceridemia: A 20-year prospective study. , 2000, Circulation.

[200]  W. A. Bradley,et al.  A macrophage receptor for apolipoprotein B48: cloning, expression, and atherosclerosis. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[201]  Y. Kako,et al.  Responses to eating: lipoproteins, lipolytic products and atherosclerosis. , 2000, Current opinion in lipidology.

[202]  J. Frohlich,et al.  Recommendations for the management and treatment of dyslipidemia. Report of the Working Group on Hypercholesterolemia and Other Dyslipidemias. , 2000, CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne.

[203]  R. Virmani,et al.  Lessons from sudden coronary death: a comprehensive morphological classification scheme for atherosclerotic lesions. , 2000, Arteriosclerosis, thrombosis, and vascular biology.

[204]  P. Barrett,et al.  Effects of continuous conjugated estrogen and micronized progesterone therapy upon lipoprotein metabolism in postmenopausal women. , 2000, Journal of lipid research.

[205]  T. Pearson,et al.  The lipid treatment assessment project (L-TAP): a multicenter survey to evaluate the percentages of dyslipidemic patients receiving lipid-lowering therapy and achieving low-density lipoprotein cholesterol goals. , 2000, Archives of internal medicine.

[206]  A. Gotto,et al.  Preventing coronary artery disease by lowering cholesterol levels: fifty years from bench to bedside. , 1999, JAMA.

[207]  R. Mahley,et al.  Pathogenesis of type III hyperlipoproteinemia (dysbetalipoproteinemia). Questions, quandaries, and paradoxes. , 1999, Journal of lipid research.

[208]  J. Isaacsohn,et al.  Colesevelam hydrochloride (cholestagel): a new, potent bile acid sequestrant associated with a low incidence of gastrointestinal side effects. , 1999, Archives of internal medicine.

[209]  R. Knopp.  Drug treatment of lipid disorders. , 1999, The New England journal of medicine.

[210]  T. Wilt,et al.  Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial Study Group. , 1999, The New England journal of medicine.

[211]  M. Koschinsky,et al.  Lipoprotein(a) and coronary heart disease risk , 1999, Current cardiology reports.

[212]  G. Thompson.  The proving of the lipid hypothesis. , 1999, Current opinion in lipidology.

[213]  C. Yutani,et al.  Characteristic cardiovascular manifestation in homozygous and heterozygous familial hypercholesterolemia. , 1999, American heart journal.

[214]  J Auwerx,et al.  Mechanism of action of fibrates on lipid and lipoprotein metabolism. , 1998, Circulation.

[215]  A. Gotto,et al.  Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study. , 1998, JAMA.

[216]  D. Levy,et al.  Prediction of coronary heart disease using risk factor categories. , 1998, Circulation.

[217]  R. Ross,et al.  Atherosclerosis is an Inflammatory Disease , 1998 .

[218]  M. Beylot,et al.  Role of human liver lipogenesis and reesterification in triglycerides secretion and in FFA reesterification. , 1998, American journal of physiology. Endocrinology and metabolism.

[219]  E. Rubin,et al.  ApoA-I deficiency causes both hypertriglyceridemia and increased atherosclerosis in human apoB transgenic mice. , 1998, Journal of lipid research.

[220]  G. Assmann,et al.  The molecular pathology of lecithin:cholesterol acyltransferase (LCAT) deficiency syndromes. , 1997, Journal of lipid research.

[221]  B. Davis,et al.  The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators. , 1996, The New England journal of medicine.

[222]  H. Ginsberg.  Diabetic Dyslipidemia: Basic Mechanisms Underlying the Common Hypertriglyceridemia and Low HDL Cholesterol Levels , 1996, Diabetes.

[223]  J. Frohlich.  Effects of alcohol on plasma lipoprotein metabolism. , 1996, Clinica chimica acta; international journal of clinical chemistry.

[224]  P. Macfarlane,et al.  Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia , 1995 .

[225]  W. Wiersinga,et al.  Prevalence and correction of hypothyroidism in a large cohort of patients referred for dyslipidemia. , 1995, Archives of internal medicine.

[226]  J. Gimble,et al.  COOH-terminal Disruption of Lipoprotein Lipase in Mice Is Lethal in Homozygotes, but Heterozygotes Have Elevated Triglycerides and Impaired Enzyme Activity (*) , 1995, The Journal of Biological Chemistry.

[227]  K. Williams,et al.  The response-to-retention hypothesis of early atherogenesis. , 1995, Arteriosclerosis, thrombosis, and vascular biology.

[228]  S. Grundy,et al.  Efficacy of Low-Dose Cholesterol-Lowering Drug Therapy in Men With Moderate Hypercholesterolemia , 1995 .

[229]  C. Semenkovich,et al.  Exercise induces human lipoprotein lipase gene expression in skeletal muscle but not adipose tissue. , 1995, The American journal of physiology.

[230]  J. Slattery,et al.  Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). 1994. , 1994, Atherosclerosis. Supplements.

[231]  C. Shear,et al.  Expanded Clinical Evaluation of Lovastatin (EXCEL) study results: two-year efficacy and safety follow-up. , 1994, The American journal of cardiology.

[232]  J. Witztum,et al.  The oxidation hypothesis of atherosclerosis , 1994, The Lancet.

[233]  E. Rubin,et al.  Apolipoprotein AI transgene corrects apolipoprotein E deficiency-induced atherosclerosis in mice. , 1994, The Journal of clinical investigation.

[234]  J. Dietschy,et al.  Role of liver in the maintenance of cholesterol and low density lipoprotein homeostasis in different animal species, including humans. , 1993, Journal of lipid research.

[235]  A. Goldberg,et al.  Efficacy of Psyllium in Reducing Serum Cholesterol Levels in Hypercholesterolemic Patients on High- or Low-Fat Diets , 1993, Annals of Internal Medicine.

[236]  R. Rosenson,et al.  Myocardial injury: the acute phase response and lipoprotein metabolism. , 1993, Journal of the American College of Cardiology.

[237]  J. Lalouel,et al.  Mutations in exon 3 of the lipoprotein lipase gene segregating in a family with hypertriglyceridemia, pancreatitis, and non-insulin-dependent diabetes. , 1993, The Journal of clinical investigation.

[238]  J. McGarry,et al.  What if Minkowski had been ageusic? An alternative angle on diabetes. , 1992, Science.

[239]  A. Tall,et al.  An interaction between the human cholesteryl ester transfer protein (CETP) and apolipoprotein A-I genes in transgenic mice results in a profound CETP-mediated depression of high density lipoprotein cholesterol levels. , 1992, The Journal of clinical investigation.

[240]  A. Tybjærg‐Hansen,et al.  IDL, VLDL, chylomicrons and atherosclerosis , 1992, European Journal of Epidemiology.

[241]  Y. Arad,et al.  Effects of lovastatin therapy on very-low-density lipoprotein triglyceride metabolism in subjects with combined hyperlipidemia: evidence for reduced assembly and secretion of triglyceride-rich lipoproteins. , 1992, Metabolism: clinical and experimental.

[242]  G. Watts,et al.  Effects on coronary artery disease of lipid-lowering diet, or diet plus cholestyramine, in the St Thomas' Atherosclerosis Regression Study (STARS) , 1992, The Lancet.

[243]  Robert V Farese,et al.  Tissue-specific regulation of lipoprotein lipase activity by insulin/glucose in normal-weight humans. , 1991, Metabolism: clinical and experimental.

[244]  R. Mahley,et al.  Genetic defects in lipoprotein metabolism. Elevation of atherogenic lipoproteins caused by impaired catabolism. , 1991, JAMA.

[245]  R. Havel,et al.  Regression of coronary atherosclerosis during treatment of familial hypercholesterolemia with combined drug regimens. , 1990, JAMA.

[246]  J J Albers,et al.  Regression of coronary artery disease as a result of intensive lipid-lowering therapy in men with high levels of apolipoprotein B. , 1990, The New England journal of medicine.

[247]  J P Matts,et al.  Effect of partial ileal bypass surgery on mortality and morbidity from coronary heart disease in patients with hypercholesterolemia. Report of the Program on the Surgical Control of the Hyperlipidemias (POSCH) , 1990, The New England journal of medicine.

[248]  M. Emi,et al.  Phenotypic expression of heterozygous lipoprotein lipase deficiency in the extended pedigree of a proband homozygous for a missense mutation. , 1990, The Journal of clinical investigation.

[249]  R. Krauss,et al.  Familial defective apolipoprotein B-100: a mutation of apolipoprotein B that causes hypercholesterolemia. , 1990, Journal of lipid research.

[250]  H. Pan,et al.  Pharmacokinetics and pharmacodynamics of pravastatin alone and with cholestyramine in hypercholesterolemia , 1990, Clinical pharmacology and therapeutics.

[251]  K. Einarsson,et al.  Low density lipoprotein receptor-binding activity in human tissues: quantitative importance of hepatic receptors and evidence for regulation of their expression in vivo. , 1990, Proceedings of the National Academy of Sciences of the United States of America.

[252]  Y. Arad,et al.  Lovastatin therapy reduces low density lipoprotein apoB levels in subjects with combined hyperlipidemia by reducing the production of apoB-containing lipoproteins: implications for the pathophysiology of apoB production. , 1990, Journal of lipid research.

[253]  S. Deeb,et al.  A splice-junction mutation responsible for familial apolipoprotein A-II deficiency. , 1990, American journal of human genetics.

[254]  J. Goldstein,et al.  Regulation of the mevalonate pathway , 1990, Nature.

[255]  N. Mcintyre.  Familial LCAT deficiency and fish-eye disease , 1988, Journal of Inherited Metabolic Disease.

[256]  J. Little,et al.  Apolipoprotein CIISt. Michael. Familial apolipoprotein CII deficiency associated with premature vascular disease. , 1987, The Journal of clinical investigation.

[257]  J. Huttunen,et al.  Helsinki Heart Study: primary-prevention trial with gemfibrozil in middle-aged men with dyslipidemia. Safety of treatment, changes in risk factors, and incidence of coronary heart disease. , 1987, The New England journal of medicine.

[258]  D H Blankenhorn,et al.  Beneficial effects of combined colestipol-niacin therapy on coronary atherosclerosis and coronary venous bypass grafts. , 1987, JAMA.

[259]  J. Stamler,et al.  Fifteen year mortality in Coronary Drug Project patients: long-term benefit with niacin. , 1986, Journal of the American College of Cardiology.

[260]  J. Neaton,et al.  Is relationship between serum cholesterol and risk of premature death from coronary heart disease continuous and graded? Findings in 356,222 primary screenees of the Multiple Risk Factor Intervention Trial (MRFIT). , 1986, JAMA.

[261]  M. Savolainen,et al.  Pathogenesis of the hypertriglyceridemia at early stages of alcoholic liver injury in the baboon. , 1986, Journal of lipid research.

[262]  M. Brown,et al.  A receptor-mediated pathway for cholesterol homeostasis. , 1986, Science.

[263]  A. Gotto,et al.  Relationship of Plasma Lipoprotein Lp(a) Levels to Race and to Apolipoprotein B , 1985, Arteriosclerosis.

[264]  D. Seidel,et al.  Role of lipoprotein-X in the pathogenesis of cholestatic hypercholesterolemia. Uptake of lipoprotein-X and its effect on 3-hydroxy-3-methylglutaryl coenzyme A reductase and chylomicron remnant removal in human fibroblasts, lymphocytes, and in the rat. , 1984, The Journal of clinical investigation.

[265]  S. Kelsey,et al.  The influence of changes in lipid values induced by cholestyramine and diet on progression of coronary artery disease: results of NHLBI Type II Coronary Intervention Study. , 1984, Circulation.

[266]  S. Grundy,et al.  Effects of interruption of the enterohepatic circulation of bile acids on the transport of very low density-lipoprotein triglycerides. , 1982, Metabolism: clinical and experimental.

[267]  D. Hunninghake,et al.  Effect of colestipol and clofibrate, singly and in combination, on plasma lipid and lipoproteins in type IIb hyperlipoproteinemia. , 1981, Metabolism: clinical and experimental.

[268]  H. G. Morgan,et al.  Cholestyramine promotes receptor-mediated low-density-lipoprotein catabolism. , 1980, The New England journal of medicine.

[269]  R. Krauss,et al.  Selective measurement of two lipase activities in postheparin plasma from normal subjects and patients with hyperlipoproteinemia. , 1974, The Journal of clinical investigation.

[270]  D. Porte,et al.  Evidence for a common, saturable, triglyceride removal mechanism for chylomicrons and very low density lipoproteins in man. , 1973, The Journal of clinical investigation.

[271]  A. Motulsky,et al.  Hyperlipidemia in coronary heart disease. II. Genetic analysis of lipid levels in 176 families and delineation of a new inherited disorder, combined hyperlipidemia. , 1973, The Journal of clinical investigation.

[272]  H. Kato,et al.  Epidemiologic studies of coronary heart disease and stroke in Japanese men living in Japan, Hawaii and California. , 1973, American journal of epidemiology.

[273]  S. Grundy,et al.  Interruption of the enterohepatic circulation of bile acids in man: comparative effects of cholestyramine and ileal exclusion on cholesterol metabolism. , 1971, The Journal of laboratory and clinical medicine.

[274]  J. Glomset,et al.  The plasma lecithins:cholesterol acyltransferase reaction. , 1968, Journal of lipid research.

[275]  I. Page.  A Journal of the American Heart Association The Lewis A. Connor Memorial Lecture Atherosclerosis. An Introduction , 2005 .

[276]  B. Staels,et al.  Bile Acid Sequestrants and the Treatment of Type 2 Diabetes Mellitus , 2012, Drugs.

[277]  E. Levy,et al.  Anderson or chylomicron retention disease: molecular impact of five mutations in the SAR1B gene on the structure and the functionality of Sar1b protein. , 2008, Molecular genetics and metabolism.

[278]  R. Steele,et al.  Statins for secondary prevention in elderly patients: a hierarchical bayesian meta-analysis. , 2008, Journal of the American College of Cardiology.

[279]  S. Schwartz,et al.  Results of the glucose-lowering effect of WelChol study (GLOWS): a randomized, double-blind, placebo-controlled pilot study evaluating the effect of colesevelam hydrochloride on glycemic control in subjects with type 2 diabetes. , 2007, Clinical therapeutics.

[280]  M. Davidson,et al.  Reporting rate of rhabdomyolysis with fenofibrate + statin versus gemfibrozil + any statin. , 2005, The American journal of cardiology.

[281]  S. Grundy,et al.  Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III Guidelines. , 2004, Journal of the American College of Cardiology.

[282]  J. van Hattum,et al.  Vitamin K deficiency and bleeding after long-term use of cholestyramine. , 2003, The Netherlands journal of medicine.

[283]  J. Vance.  Molecular and cell biology of phosphatidylserine and phosphatidylethanolamine metabolism. , 2003, Progress in nucleic acid research and molecular biology.

[284]  A. Bowcock,et al.  AGPAT2 is mutated in congenital generalized lipodystrophy linked to chromosome 9q34 , 2002, Nature Genetics.

[285]  S. Yusuf.  MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20536 high-risk individuals: a randomised placebo-controlled trial. Commentary , 2002 .

[286]  M. Friger,et al.  Usefulness of lipoprotein changes during acute coronary syndromes for predicting postdischarge lipoprotein levels. , 2002, The American journal of cardiology.

[287]  J. Slotte,et al.  Cholesterol interactions with phospholipids in membranes. , 2002, Progress in lipid research.

[288]  L. Aggerbeck,et al.  The role of the microsomal triglygeride transfer protein in abetalipoproteinemia. , 2000, Annual review of nutrition.

[289]  R. Mahley,et al.  Apolipoprotein E: far more than a lipid transport protein. , 2000, Annual review of genomics and human genetics.

[290]  I. Tabas,et al.  Nonoxidative modifications of lipoproteins in atherogenesis. , 1999, Annual review of nutrition.

[291]  R. Mahley,et al.  Remnant lipoprotein metabolism: key pathways involving cell-surface heparan sulfate proteoglycans and apolipoprotein E. , 1999, Journal of lipid research.

[292]  G. Lippi,et al.  Usefulness of lipids, lipoprotein(a) and fibrinogen measurements in identifying subjects at risk of occlusive complications following vascular and endovascular surgery. , 1998, Scandinavian journal of clinical and laboratory investigation.

[293]  H. Bryant,et al.  Hypocholesterolemic activity of raloxifene (LY139481): pharmacological characterization as a selective estrogen receptor modulator. , 1997, The Journal of pharmacology and experimental therapeutics.

[294]  D R Illingworth,et al.  The efficacy and six-week tolerability of simvastatin 80 and 160 mg/day. , 1997, The American journal of cardiology.

[295]  W. Duane,et al.  Abnormal bile acid absorption in familial hypertriglyceridemia. , 1995, Journal of lipid research.

[296]  J. Webster,et al.  Colestipol at varying dosage intervals in the treatment of moderate hypercholesterolaemia. , 1994, British journal of clinical pharmacology.

[297]  K. Weisgraber.  Apolipoprotein E: structure-function relationships. , 1994, Advances in protein chemistry.

[298]  D. Gazit,et al.  Osteoporosis and increased bone fractures in cerebrotendinous xanthomatosis. , 1993, Metabolism: clinical and experimental.

[299]  R. Hegele,et al.  Human hepatic lipase mutations and polymorphisms , 1992, Human mutation.

[300]  B. Lewis,et al.  Familial chylomicronemia due to a circulating inhibitor of lipoprotein lipase activity. , 1983, Journal of lipid research.

[301]  S. Grundy,et al.  Mevinolin stimulates receptor-mediated clearance of low density lipoprotein from plasma in familial hypercholesterolemia heterozygotes. , 1983, Transactions of the Association of American Physicians.

[302]  R. Vranckx,et al.  Inhibition of lipoprotein lipase activity by a monoclonal immunoglobulin in autoimmune hyperlipidemia. , 1977, Atherosclerosis.

[303]  Luquan Wang,et al.  Materials and Methods Figs. S1 to S4 Tables S1 and S2 References Niemann-pick C1 like 1 Protein Is Critical for Intestinal Cholesterol Absorption , 2022 .